Buerger's Disease
Buerger's disease or thromboangiitis obliterans, a rare small-to-medium-sized vessel vasculitis, is significantly associated with augmented risk of arterial occlusion. Exploring the drug discovery for rare cardiovascular diseases such as Buerger's disease requires a special combination of expertise and coordination. Committed to the development of therapeutics for these conditions, Protheragen provides end-to-end drug discovery and development solutions.
Introduction to Buerger's Disease
Buerger's disease is a non-atherosclerotic inflammatory vaso-occlusive disease. Pathologically, it is reported a panangiitis of medium and small blood vessels, involving arteries and their adjacent veins, especially the distal extremities (feet and hands). In the U.S., rates for Buerger's disease have been decreasing with the decline in smoking and are currently between 12.6 and 20 per 100,000 individuals.
Fig.1 Pathogenesis of atherosclerotic PAD and Buerger's disease. (Ribieras, A. J., et al., 2022)Pathogenesis of Buerger's Disease
Pathologically, the evolution of Buerger's disease is divided into 3 different stages. Characteristically, a hypercellular inflammatory infiltrate is found within the vessel lumen and is most diagnostic in an acute phase. Local prothrombotic state secondary to vascular inflammation results in vaso-occlusion and thereafter microabscess formation. Granulomatous inflammation occurs subacutely and the thrombus is organized and recanalized. When the thrombus organizes chronically, vascular fibrosis results, resulting in a stenotic arterial lumen that can resemble atherosclerotic lesions in the setting.
Fig.2 Potential effects of distinct angiogenic therapy strategies. (Ribieras, A. J., et al., 2022)Therapeutics Development for Buerger's Disease
| Drug Name | Mechanism of Action | Targets | NCT Number | Research Phase |
|---|---|---|---|---|
| Allogeneic mesenchymal stromal cells | By their immunomodulatory and pro-angiogenic features, inducing angiogenesis and repairing of tissues. | / | NCT05854615 | Phase IV |
| Botulinum toxin | By inhibiting the activity of the sympathetic nerves, vasodilation occurs producing an increase in blood flow and reduction of ischemic symptoms in affected extremities. | SNAP-25 | NCT05698979 | Phase III |
| Selexipag | Through exerting vasodilator and anti-platelet aggregation action. | PGI2 receptor | NCT04914247 | N/A |
| Adipose-derived regenerative cells | Via their multipotent stem cell characteristics, they stimulate angiogenesis and tissue regeneration. | / | NCT02864654 | Phase I/II |
Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a therapy plan recommendation. For guidance on therapy options, please visit a regular hospital.
Our Services
With a working group comprised of experienced scientists and experts from the industry, we are dedicated to driving your projects forward accurately and effectively. From diagnostics and therapeutics to disease model systems, we offer a range of expertise to meet all your research requirements. This comprehensive strategy serves to not only shorten the development timeline but also to increase the likelihood of success.
Therapeutic Development Services
Animal Model Development for Buerger's Disease
Animal models play a pivotal role in understanding the pathology of Buerger's disease. By offering customized animal model development services, we enable the researchers to receive useful insight, speed up the preclinical research state, and elevate the chances of positive therapy results.
The animal models that mimic Buerger's disease by surgical procedures induction ischemia and vasculitis are applied in the preclinical evaluation.
Optional models:
- Femoral artery ligation model
- Gelatin sponge particle implantation model
- Sodium laurate and dihydrotestosterone implantation model
- Other models
Focusing on innovation and the client we customize our services to stand by your specific goals and schedule. Protheragen's infrastructure covers the whole range of preclinical services with a focus on pharmacokinetic studies and drug safety assessment. State-of-the-art technology and personalized protocols mean pinpoint accuracy and reduced time for discoveries. If you are interested in our services, don't hesitate to contact us.
References
- Ribieras, Antoine J et al. "Therapeutic angiogenesis in Buerger's disease: reviewing the treatment landscape." Therapeutic advances in rare disease 3 (2022): 26330040211070295.
- Fazeli, Bahare et al. "Recent Updates and Advances in Winiwarter-Buerger Disease (Thromboangiitis Obliterans): Biomolecular Mechanisms, Diagnostics and Clinical Consequences." Diagnostics (Basel, Switzerland) 11.10 (2021): 1736.
For research use only, not for clinical use.